Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: Continuous evolution of Omicron has led to the emergence of multiple variants with growth advantages, and mutations in their receptor-binding domain have converged on several hotspots, allowing them to evade neutralizing antibody drugs and convalescent plasma. Breakthrough infections of BA.2 and BA.5 have reduced the diversity of neutralizing antibody binding sites and promoted convergent evolution in the RBD.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Multidisciplinary Sciences
Kang Wang et al.
Summary: The Omicron variant of SARS-CoV-2 is highly resistant to neutralizing antibodies, which raises concerns about the effectiveness of antibody therapies and vaccines. A study found that individuals who received two or three doses of an inactivated SARS-CoV-2 vaccine had varying rates of seroconversion for neutralizing antibodies. The effectiveness of neutralizing antibodies against Omicron was significantly lower in individuals who received three vaccine doses. However, monoclonal antibodies derived from individuals who received three vaccine doses showed strong neutralizing activity against all variants of concern, including Omicron.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Multidisciplinary Sciences
Young-Jun Park et al.
Summary: Understanding broadly neutralizing sarbecovirus antibody responses is crucial for developing countermeasures against SARS-CoV-2 variants and future sarbecoviruses. The human monoclonal antibody S2K146 has been found to broadly neutralize ACE2-binding viruses and shows potential for clinical development. Conserved ACE2-binding residues could be leveraged for developing vaccines that elicit broad immunity.
Article
Biochemistry & Molecular Biology
Rungtiwa Nutalai et al.
Summary: This study compares the neutralization of Omicron variants of SARS-CoV-2 and finds that differences in neutralization mostly arise from variations in residues bordering the ACE2 binding site. Analysis of monoclonal antibodies isolated from vaccinated individuals shows that they can effectively neutralize early pandemic strains and exhibit broad reactivity with variants.
Article
Microbiology
Xiaofei Wang et al.
Summary: The study reveals that the monoclonal antibody 35B5 exhibits potent neutralizing efficacy against the SARS-CoV-2 Omicron variant. Despite the multiple mutations in the Omicron spike protein, 35B5 can still effectively target and neutralize the virus.
CELL HOST & MICROBE
(2022)
Article
Immunology
Zijun Wang et al.
Summary: SARS-CoV-2 infection or vaccination induces neutralizing antibody responses targeting the receptor-binding domain (RBD) and the N-terminal domain (NTD) of the spike protein. This study identifies different groups of neutralizing antibodies, including some that can neutralize the Omicron variant. Structural analysis reveals the mechanism of action of broad neutralizers.
News Item
Infectious Diseases
Sharmila Devi
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Qin Hong et al.
Summary: This study used cryo-electron microscopy to reveal the structural features of the Omicron variant spike protein and its interactions with the ACE2 receptor and antibodies, providing important insights for further research and design of vaccines targeting this variant.
Article
Biochemistry & Molecular Biology
Ziyad Al-Aly et al.
Summary: This study analyzed the US Department of Veterans Affairs national healthcare databases to investigate the occurrence of Long COVID and death risk after breakthrough SARS-CoV-2 infection. The findings showed that vaccination significantly reduced the risk of death and post-acute sequelae but did not eliminate them completely. These results underscore the importance of further research on prevention and post-acute care for breakthrough infections.
Article
Medicine, General & Internal
A. M. Price et al.
Summary: In this study evaluating BNT162b2, vaccine effectiveness against hospitalization for Covid-19 in the delta-predominant period among adolescents 12 to 18 years of age was more than 90%; during the omicron period, vaccine effectiveness was 40% against hospitalization and 79% against critical illness. Vaccine effectiveness against hospitalization was 68% among children 5 to 11 years of age.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
Lihong Liu et al.
Summary: This study identified a human monoclonal antibody, 10-40, that can neutralize or bind all tested sarbecoviruses and provide protection against SARS-CoV-2 and SARS-CoV in vivo. Comparative studies showed that 10-40 has the broadest effectiveness against sarbecoviruses among other receptor-binding domain (RBD)-directed antibodies, making it a promising candidate for pandemic preparedness. Structural analyses also revealed a conserved epitope cluster and a distinct antibody class with a common CDRH3 motif.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Cell Biology
Kathryn Westendorf et al.
Summary: A monoclonal antibody named LY-CoV1404 has been successfully isolated, which demonstrates highly potent neutralization against multiple variants of the SARS-CoV-2 virus. The binding site of LY-CoV1404 remains relatively conserved, allowing it to maintain its activity. This finding suggests that LY-CoV1404 has the potential to be an effective therapeutic agent against all known variants.
Article
Microbiology
Viviana Simon et al.
Summary: This study provides a detailed description of the PARIS/SPARTA cohorts, harmonized assays, and analysis methods, as well as case definitions for SARS-CoV-2 infection and reinfection. Determining reinfection rates and correlates of protection against SARS-CoV-2 infection induced by both natural infection and vaccination is of high significance for the prevention and control of COVID-19.
Letter
Medicine, General & Internal
Elena Azzolini et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Multidisciplinary Sciences
Qian Wang et al.
Summary: SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have become dominant in the United States and South Africa, raising concerns about their ability to evade neutralizing antibodies and compromise the efficacy of COVID-19 vaccines and therapeutic monoclonals. A systematic antigenic analysis reveals that BA.2.12.1 and BA.4/5 have different levels of resistance to antibodies, with BA.2.12.1 being modestly resistant and BA.4/5 being substantially resistant. Certain mutations in the spike protein facilitate antibody escape, but compromise the spike affinity for the viral receptor. Only bebtelovimab retains full potency against both subvariants.
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: Omicron sublineages BA.2.12.1, BA.4 and BA.5 have higher transmissibility and increased evasion of neutralizing antibodies compared to the BA.2 lineage. They exhibit similar binding affinities to the ACE2 receptor as BA.2. BA.1 infection after vaccination boosts humoral immune memory against wild-type SARS-CoV-2, but these antibodies are largely evaded by BA.2 and BA.4/BA.5 variants.
Article
Multidisciplinary Sciences
Biao Zhou et al.
Summary: Here, researchers successfully screened and isolated a broadly neutralizing antibody ZCB11 that can neutralize all variants of concern of SARS-CoV-2, showing particularly potent activity against the Omicron variant. Further studies demonstrated that ZCB11 predominantly interacts with the receptor-binding domain of the Omicron variant, blocking ACE2 binding. Prophylactic or therapeutic administration of ZCB11 protected against lung infection in animal models challenged with the Omicron variant.
NATURE COMMUNICATIONS
(2022)
Article
Microbiology
Craig Fenwick et al.
Summary: A monoclonal antibody named P2G3 isolated from a previously infected vaccinated donor shows strong neutralizing activity against the SARS-CoV-2 Omicron variant and provides complete prophylactic or therapeutic protection when used alone or in combination with another antibody. The unique epitope of P2G3 may have important implications for combating the Omicron variant.
NATURE MICROBIOLOGY
(2022)
Article
Immunology
Sai Luo et al.
Summary: The Omicron subvariants of SARS-CoV-2 have caused a global crisis as they are resistant to most approved neutralizing antibodies and evade vaccination-induced antibodies. In this study, researchers describe a mouse model that produces a diverse repertoire of humanized SARS-CoV-2 neutralizing antibodies. Through immunization with SARS-CoV-2 spike protein, they identified a potent and broadly neutralizing antibody, SP1-77, which bound to the receptor-binding domain in a unique way. This antibody showed potential therapeutic value and could inform vaccine strategies. Furthermore, this humanized mouse model may contribute to the development of therapeutic antibodies against future SARS-CoV-2 variants and other pathogens.
SCIENCE IMMUNOLOGY
(2022)
Article
Microbiology
Yunlong Cao et al.
Summary: The newly emerged SARS-CoV-2 Omicron subvariant, BA.2.75, has shown a growth advantage over other circulating variants in India. This study reveals that BA.2.75 has a higher affinity for the host receptor ACE2 and exhibits increased low-pH-endosomal cell entry. It also demonstrates reduced evasion of humoral immunity from certain convalescent plasma, while showing a distinct neutralizing antibody escape pattern. These findings suggest that BA.2.75 may become the dominant variant following BA.4/BA.5.
CELL HOST & MICROBE
(2022)
Article
Microbiology
Qian Wang et al.
Summary: The newly emerged SARS-CoV-2 Omicron subvariant BA.2.75 exhibits moderate resistance to neutralization by sera from vaccinated/boosted individuals compared to the currently circulating BA.2, but is more sensitive than BA.4/5. BA.2.75 shows heightened resistance to class 1 and class 3 monoclonal antibodies targeting the spike-receptor-binding domain, while gaining sensitivity to class 2 antibodies. The resistance is mainly conferred by two mutations. BA.2.75 also shows slight resistance to a therapeutic antibody with potent activity against all Omicron subvariants. Additionally, BA.2.75 exhibits higher binding affinity to the host receptor ACE2 compared to other Omicron subvariants.
CELL HOST & MICROBE
(2022)
Article
Medicine, General & Internal
Dan-Yu Lin et al.
Summary: The study shows that COVID-19 vaccination and prior SARS-CoV-2 infection are associated with the risk of SARS-CoV-2 infection, hospitalization, and death. While vaccination can lower the risk of infection, the protection wanes over time.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
News Item
Multidisciplinary Sciences
Ewen Callaway
Summary: Descendants of Omicron are spreading rapidly worldwide, and the same mutations are emerging repeatedly.
Letter
Medicine, General & Internal
Nicole P. Hachmann et al.
Summary: Neutralization titers against omicron subvariant BA.4.6 were lower compared to subvariants BA.4 and BA.5 induced by infection or vaccination against SARS-CoV-2.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Fiona P. Havers et al.
Summary: Understanding the factors that contribute to hospitalization in vaccinated individuals is crucial for combating COVID-19. This study found that unvaccinated adults were more likely to be hospitalized compared to vaccinated adults, with the lowest hospitalization rates observed in those who had received a booster dose.
JAMA INTERNAL MEDICINE
(2022)
Article
Immunology
Daniel Ayoubkhani et al.
Summary: Vaccination reduces the incidence of long COVID, highlighting the importance of increasing population-level vaccine uptake through public health initiatives.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Letter
Cell Biology
Lei Wang et al.
Article
Multidisciplinary Sciences
Sho Iketani et al.
Summary: The identification of the Omicron variant of SARS-CoV-2 in Botswana in November 2021 sparked concern due to the spike protein alterations that could potentially evade antibodies. Further studies showed that the Omicron sublineages, BA.1+R346K and BA.2, are antigenically similar to the wild-type virus and pose similar risks to the effectiveness of current vaccines. BA.2 also demonstrated resistance to many neutralizing monoclonal antibodies, highlighting the challenges in developing effective therapeutic options.
Article
Medicine, General & Internal
Mark W. Tenforde et al.
Summary: This study evaluated the association between mRNA COVID-19 vaccines and COVID-19 hospitalization, as well as disease progression to critical illness among hospitalized patients. The results showed that vaccination with mRNA COVID-19 vaccines significantly decreased the likelihood of COVID-19 hospitalization and disease progression to death or mechanical ventilation.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Cell Biology
Yunlong Cao et al.
Summary: The study found that the diversity of anti-RBD NAbs plays a major role in neutralization against SARS-CoV-2 variants, especially 501Y.V2, with E484K being the dominant cause of neutralization reduction. Specific antibodies respond differently to mutations in RBD variants, with lower diversity observed in NTD antibodies. RBD-subunit vaccinees exhibit higher tolerance to neutralization against variants, while extending the interval between doses of ZF2001 enhances neutralizing activity and tolerance to variants.
Letter
Cell Biology
Shuo Du et al.
Article
Virology
Aine O'Toole et al.
Summary: The global virus genomics community has responded unprecedentedly to the SARS-CoV-2 pandemic, leading to significant advances in 'real-time' generation and sharing of genomic data. The development of new analytical methods, such as pangolin, has been necessary to handle the rapid growth in virus genome data production. Pangolin has processed nearly two million virus genomes, aiding in SARS-CoV-2 genomic epidemiology and providing researchers with valuable information about the pandemic's transmission lineages.
Article
Multidisciplinary Sciences
Daniel Wrapp et al.
Article
Multidisciplinary Sciences
Dora Pinto et al.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Article
Multidisciplinary Sciences
Seth J. Zost et al.
Article
Multidisciplinary Sciences
Kui K. Chan et al.
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
Article
Multidisciplinary Sciences
Michael Baym et al.
Article
Biochemical Research Methods
Ben Langmead et al.
Letter
Biotechnology & Applied Microbiology
James T. Robinson et al.
NATURE BIOTECHNOLOGY
(2011)
Article
Multidisciplinary Sciences
DJ Smith et al.
